Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease

Wen Hsin Chang, Dau Ming Niu, Chi Yu Lu, Shyr Yi Lin, Ta Chih Liu, Jan Gowth Chang

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.

Original languageEnglish
Article numbere0175929
JournalPLoS One
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

Fabry Disease
Amiloride
alternative splicing
Alternative Splicing
Histone Code
Modulation
Inborn Genetic Diseases
Histones
Introns
Substitution reactions
Cells
Association reactions
histones
introns
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chang, W. H., Niu, D. M., Lu, C. Y., Lin, S. Y., Liu, T. C., & Chang, J. G. (2017). Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease. PLoS One, 12(4), [e0175929]. https://doi.org/10.1371/journal.pone.0175929

Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease. / Chang, Wen Hsin; Niu, Dau Ming; Lu, Chi Yu; Lin, Shyr Yi; Liu, Ta Chih; Chang, Jan Gowth.

In: PLoS One, Vol. 12, No. 4, e0175929, 01.04.2017.

Research output: Contribution to journalArticle

Chang, Wen Hsin ; Niu, Dau Ming ; Lu, Chi Yu ; Lin, Shyr Yi ; Liu, Ta Chih ; Chang, Jan Gowth. / Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{1cb1b9b5e23f4b8ab1c4547979820067,
title = "Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease",
abstract = "While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.",
author = "Chang, {Wen Hsin} and Niu, {Dau Ming} and Lu, {Chi Yu} and Lin, {Shyr Yi} and Liu, {Ta Chih} and Chang, {Jan Gowth}",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0175929",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease

AU - Chang, Wen Hsin

AU - Niu, Dau Ming

AU - Lu, Chi Yu

AU - Lin, Shyr Yi

AU - Liu, Ta Chih

AU - Chang, Jan Gowth

PY - 2017/4/1

Y1 - 2017/4/1

N2 - While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.

AB - While a base substitution in intron 4 of GLA (IVS4+919G>A) that causes aberrant alternative splicing resulting in Fabry disease has been reported, its molecular mechanism remains unclear. Here we reported that upon IVS4+919G>A transversion, H3K36me3 was enriched across the alternatively spliced region. PSIP1, an adapter of H3K36me3, together with Hsp70 and NONO were recruited and formed a complex with SF2/ASF and SRp20, which further promoted GLA splicing. Amiloride, a splicing regulator in cancer cells, could reverse aberrant histone modification patterns and disrupt the association of splicing complex with GLA. It could also reverse aberrant GLA splicing in a PP1-dependant manner. Our findings revealed the alternative splicing mechanism of GLA (IVS4+919G>A), and a potential treatment for this specific genetic type of Fabry disease by amiloride in the future.

UR - http://www.scopus.com/inward/record.url?scp=85018162011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018162011&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0175929

DO - 10.1371/journal.pone.0175929

M3 - Article

C2 - 28430823

AN - SCOPUS:85018162011

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0175929

ER -